HAYDEN LATOUR: Open Payments
NPI 1982322988 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,462 in 70 payments from 15 companies in 2025. Trend: 2023 $1,140 · 2024 $1,288 · 2025 $1,462
Food & beverage: $1,462
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 14 | $373 |
| ABBVIE INC. | 14 | $158 |
| Regeneron Healthcare Solutions, Inc. | 5 | $148 |
| Organon LLC | 9 | $146 |
| Lilly USA, LLC | 8 | $129 |
| REVANCE THERAPEUTICS, INC. | 1 | $115 |
| UCB, Inc. | 4 | $96 |
| Galderma Laboratories, L.P. | 4 | $79 |
| Amgen Inc. | 4 | $74 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $45 |
Products named: DUPIXENT, SKYRIZI, TALTZ, DAXXIFY, Bimzelx, NEMLUVIO, OTEZLA, VTAMA.
Industry payments across LA — which companies pay providers there.
